Cas9 Stable Cell Line - MGC803

The MGC803 cell line is a human gastric cancer cell line established from tumor tissue of gastric cancer patients. It is an important model for studying the biology, molecular mechanisms, and therapeutic interventions of gastric cancer. The Cas9 Stable Cell Line - MGC803 is obtained through genetic engineering of this parent cell line, enabling it to stably express CRISPR-associated protein 9 (Cas9). This cell line maintains the stability of Cas9 protein expression during passage, allowing for efficient and reproducible genome editing without repeated transfections. Key features of this cell line include high editing efficiency, compatibility with single-guide RNA (sgRNA) delivery for targeted modification, and preservation of the original phenotype of MGC803 cells—making it ideal for loss-of-function studies, gene knockout validation, and functional genomics screening in gastric cancer research.

The Cas9 Stable Cell Line - MGC803 is widely used in multiple fields of oncology and genetics research. It enables high-throughput CRISPR screening to identify key genes, drug targets, or drug resistance mechanisms in gastric cancer, and allows for genome-wide or pathway analysis using mixed sgRNA libraries. In drug development, this cell line helps construct homologous knockout models (e.g., TP53, KRAS, or CDH1 mutations), enabling the evaluation of treatment efficacy and resistance patterns within a controlled genetic context. It also supports functional validation of tumor suppressor genes, oncogenes, and signaling pathways through precise gene knockout, knock-in, or base editing, thereby accelerating research into the mechanisms of gastric cancer progression and metastasis. Furthermore, this cell line plays a crucial role in synthetic lethality screening, biomarker identification, and the construction of personalized cancer models through patient-derived xenograft (PDX) engineering.